Changes in the cortical GABAergic inhibitory system in a Spinal Muscular Atrophy mouse model

Changes in the cortical GABAergic inhibitory system in a Spinal Muscular Atrophy mouse model

Cell Death and Disease, 28 February 2026
Changes in the cortical GABAergic inhibitory system in a Spinal Muscular Atrophy mouse model

Menduti G, Ferrini F, Caretto A, Hassan A, di Vito R, Beltrando G, Marnetto D, Usiello A, Di Cunto F, Boido M, Vercelli A

NICO Research Group: Brain development and disease

 

The cortical motor network excitatory-inhibitory (E/I) imbalance contributes to several neurodegenerative movement disorders. Spinal Muscular Atrophy (SMA) is a neuromuscular disease due to the lack of Survival Motor Neuron (SMN) protein, characterized by lower motor neuron (MN) degeneration and muscle atrophy. However, evidence shows that SMA patients display motor cortex abnormalities correlating with disease severity, suggesting altered maturation and maladaptive plasticity potentially contributing to upper MN vulnerability. This raises questions about cortical involvement and highlights the need for preclinical studies to clarify underlying mechanisms, given the limited accessibility of early-stage, untreated brain tissue from SMA patients.

In agreement, our previous work in SMA mice revealed upper MN vulnerability, indicating SMA pathogenesis is far more complex than classically conceived. Here, by employing a combination of imaging, molecular techniques, and electrophysiological characterization of cortical inhibitory neurotransmission, we dissected GABAergic signalling, metabolism, and interneuron function in the sensorimotor cortex and primary neuron-astrocyte co-cultures of a severe SMA mouse model.

Additionally, we conducted bioinformatic analyses and biochemical assays to assess age-dependent modulation of neurotransmitter pathways and quantify key metabolites across different stages of the disease, with the overall aim of evaluating correlations between GABA levels, its precursor glutamine, the expression of synthetic enzymes (GAD65/67), and the density of Parvalbumin-positive interneurons with SMN deficiency. We unveiled a significant association between SMN deficiency and impaired density, morphology and signalling of GABAergic Parvalbumin positive interneurons in the sensorimotor cortex of late-stage SMA mice, suggesting E/I imbalance and possibly contributing to shape upper MN vulnerability.

We also highlighted the pivotal role of SMN, as involved in pre-mRNA splicing, in its impact on neuronal-astrocyte interactions regulating GABA metabolism, release and reuptake. These findings underscore a role for altered motor cortical GABAergic neurotransmission in SMA progression and offer a new key perspective to achieving novel, comprehensive therapeutic approaches.

OPEN ACCESS go to full article

 

from the left: dr. Giovanna Menduti, prof. Alessandro Vercelli and prof. Marina Boido.

 

This schematic illustrates how inhibitory signaling is altered in the motor cortex of SMA mice compared to healthy controls. In SMA, low SMN levels affect how neurons produce and use GABA, the brain’s main inhibitory neurotransmitter. The supply of key metabolic precursors from astrocytes to neurons is reduced, leading to lower GABA production. As a result, inhibitory communication between brain cells becomes weaker. There are fewer inhibitory connections, and parvalbumin-positive (PV+) interneurons, the specialized cells that help maintain network balance, show structural changes and reduced function. At the same time, astrocytes do not regulate GABA properly, further affecting this delicate balance. Overall, these alterations reduce inhibitory control within motor cortical circuits.

Related News

Motor Neuron Diseases 2026 – IV edition

SAVE THE DATE! The fourth edition of the meeting is scheduled, again in Turin, on November 6 and 7, 2026. The conference, organized by prof. Marina Boido and Serena Stanga, will still focus on Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA), two severe neurological pathologies affecting motor neurons and causing their progressive degeneration. 

Alzheimer’s disease: biological mechanisms, epigenetics, and emerging technologies for early diagnosis

Thursday, February 5, 2026 - Presentation of research projects supported by the CRT Foundation (Ordinary Grants)

10H-phenothiazine exerts beneficial effects in spinal muscular atrophy in vitro and in vivo models

Scientific Reports - Drug repositioning may represent a valid strategy to identify new treatments by repurposing FDA/EMA-approved drugs that, combined with the available ones, could delay neurodegeneration. To this aim, for the first time we used primary cortical neurons derived from the SMNΔ7 mice as defective in vitro disease model, to preliminary assess drug efficacy on neuronal survival and morphology.

Subscribe to our newsletter
Stay updated on news and projects

Subscribe to our newsletter
Stay updated on news and projects